U.S. Markets open in 6 hrs 44 mins

Today's Research Reports on Stocks to Watch: KalVista Pharmaceuticals and Nutanix Inc.

NEW YORK, NY / ACCESSWIRE / October 11, 2017 / U.S. major indexes continued to hit new record highs Tuesday as consumer staples were lifted by Wal-Mart Stores Inc.'s announcement of a $20 billion share repurchase program. The Dow Jones Industrial Average gained 0.31 percent to close at a record 22,830.68, its 47th record close in 2017, while the S&P 500 Index hit an intra-day record of 2,555.23 before settling to close at 2,550.64, an increase of 0.23 percent. The NASDAQ Composite Index hit an intra-day record of 6,608.30 before settling to close at 6,587.25, an increase of 0.11 percent. Corporate earnings will now be a main focus amongst investors as earnings season is set to kick off this week.

"We think valuations are fair and we're not expecting any big surprises out of earnings season, which should be pretty strong," said Michael Matousek, head trader at U.S. Global Investors Inc. in San Antonio, according to MarketWatch. "I don't think we're going to see major moves to the upside or the downside until earnings, because people are waiting to see where major companies like [Facebook Inc.] come in, but there is optimism."

RDI Initiates Coverage on:

KalVista Pharmaceuticals Inc.
https://rdinvesting.com/news/?ticker=KALV

Nutanix Inc.
https://rdinvesting.com/news/?ticker=NTNX

KalVista Pharmaceuticals Inc.'s stock jumped 38.64% Tuesday, to close the day at $10.19. The stock recorded a trading volume of 3,547,940 shares, which was above its three months average volume of 16,748 shares. In the last year KalVista Pharmaceuticals Inc.'s shares have traded in a range of 6.09 - 15.80. The share price has gained 67.32% from its 52 week low. The company's shares are currently trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $7.23 is at its 200-day moving average of $7.23. Shares of KalVista Pharmaceuticals have gained approximately 44.13 percent year-to-date.

Access RDI's KalVista Pharmaceuticals Inc. Research Report at:
https://rdinvesting.com/news/?ticker=KALV

On Tuesday, shares of Nutanix Inc. recorded a trading volume of 15,571,907 shares, which was above the three months average volume of 4,114,600 shares. The stock ended the day 9.87% higher at 25.61. The share price has gained 20.74% from its 52 week low with a 52 week trading range of 21.21 - 35.90.The company's shares are currently trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $22.72 is at its 200-day moving average of $22.72. Shares of Nutanix have fallen approximately 3.58 percent year-to-date.

Access RDI's Nutanix Inc. Research Report at:
https://rdinvesting.com/news/?ticker=NTNX

Our Actionable Research on KalVista Pharmaceuticals Inc. (NASDAQ: KALV) and Nutanix Inc. (NASDAQ: NTNX) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com